Loading clinical trials...
Loading clinical trials...
Epilepsy is a syndrome of episodic brain dysfunction characterized by recurrent seemingly unpredictable spontaneous seizures. The occurrence of the seizure in patients without any forewarning is the most debilitating aspect of the disease. The Epicall system is intended for early detection of seizure related life threatening events by monitoring per-seizures biomarkers. The system is based on a sticker placed on the side of the face. The external sticker incorporates EOG (electrooculograph electrode) and PPG (photoplethysmograph electrode) sensors for continuous monitoring of: 1. Heart Rate (base line, increase, decrease, asystole). 2. Extra ocular eye movement (blinking, eye deviation, roving eye movements).
Age
1 - 18 years
Sex
ALL
Healthy Volunteers
No
Asaf Harofeh Medical Center
Zrifin, Israel
Start Date
November 1, 2011
Primary Completion Date
June 1, 2012
Last Updated
September 20, 2011
30
ESTIMATED participants
Epicall
DEVICE
Lead Sponsor
Epicall LTD
NCT06700356
NCT05077904
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05667142